Inhibikase Therapeutics, Inc.

US$1.50As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:IKTHealthcare
Country USA
PE (Fwd) •••
TSR 6Y CAGR (43.27%)
Div yield —
ROE (51.96%)
Biotechnology
Beta (5Y) 0.94
PE TTM —
TSR TTM 2.04%
Mkt cap US$273.1M
ROIC (35.46%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$1.95
29.84%
(21.48%)
Hold 0|5|9|10|1
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.03
0.03
0.03
0.03
31.82%
21.81%
26.43%
14.30%
Revenue$M
12.24
12.96
13.31
13.61
(5.56%)
1.54%
5.59%
9.95%
Peers (US$273.1M)
Cap (US$)
PE
276.8M
5.834x
269.1M
179.9x
Capital
TTM
5Y
10Y
Leveragex
0.821
(0.458)
(0.318)
EBIT/Intx
0.507
1.886
1.749
Own earn%
84.68
(38.83)
(41.84)
Sh yield%
40.71
38.18
35.70
Owners
Insiders/Inst%
10.29
45.61
Short interest%
3.05
SBC / revenue%
5.55
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
16
Op margin range%
0–8
$1 testx
—
Incr. ROIC%
6